文献速递哮喘

中国咳嗽变异性哮喘多中心前瞻性观察研究:临床特征、气道炎症与预后

[A multicenter, prospective, observational study of cough variant asthma in China: clinical features, airway inflammation, and prognosis].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2025-01-01

该研究为全国17家医院多中心前瞻性队列,纳入342例新诊断咳嗽变异性哮喘(CVA)患者,抗哮喘治疗并随访6个月。治疗4个月时咳嗽改善最大,36.5%患者6个月咳嗽仍未完全缓解;2型炎症是咳嗽完全缓解的预测因素。

要点

  • CVA抗哮喘治疗4个月时咳嗽改善最大,疗程可能需超过4个月。
  • 36.5%的CVA患者经6个月治疗咳嗽仍未完全缓解。
  • 2型炎症是CVA咳嗽完全缓解的预测因素(HR=1.733)。

核心结论

  • CVA患者抗哮喘治疗4个月后咳嗽获得最大改善,提示疗程可能需要持续4个月以上。
  • 部分CVA患者经治疗后咳嗽仍不能完全缓解,可能与非2型炎症有关。

研究设计与样本

  • 全国多中心、前瞻性观察队列研究,2017年12月至2020年1月从全国17家医院招募新诊断CVA患者。
  • 患者接受抗哮喘治疗并随访6个月,评估咳嗽程度、肺功能、诱导痰细胞学和FeNO变化。
  • 共纳入342例CVA患者,男114例、女228例,年龄18~70(41.2±12.9)岁。

主要发现

  • 治疗2个月后肺功能指标、FeNO及诱导痰嗜酸性粒细胞百分比中位值基本恢复至正常范围。
  • 治疗4个月时患者咳嗽症状达到最大程度改善。
  • 125例(36.5%)CVA患者经6个月治疗咳嗽仍未能完全缓解。
  • 咳嗽未完全缓解者较完全缓解者年龄更大、病程更长、基线诱导痰中性粒细胞百分比更高。
  • 咳嗽未完全缓解者诱导痰嗜酸性粒细胞百分比、FeNO水平及2型炎症比例更低[42.4%(53/125)比65.3%(141/216),P=0.001]。

关键数值与推荐

  • 2型炎症定义为至少一项:诱导痰嗜酸性粒细胞百分比≥3%,FeNO≥50 ppb,或外周血嗜酸性粒细胞计数≥0.3×10⁹/L。
  • 2型炎症是咳嗽完全缓解的预测因素(HR=1.733,95%CI:1.188~2.528,P=0.004)。

临床怎么用

  • CVA抗哮喘治疗疗程可能需要持续4个月以上以评估咳嗽最大改善。
  • 对非2型炎症特征的CVA患者,需关注咳嗽可能不完全缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the changes in cough severity, lung function, and airway inflammation after anti-asthma treatment in patients with cough variant asthma (CVA), as well as the factors related to treatment response. Methods: This nationwide, multicenter, prospective observational cohort study enrolled newly diagnosed cough-variant asthma (CVA) patients from 17 hospitals across China between December 2017 and January 2020. Patients received anti-asthma treatment and were followed for 6 months. Changes in cough severity, lung function, induced sputum and fractional exhaled nitric oxide (FeNO) were assessed. Type 2 inflammation was defined as sputum eosinophils ≥3%, and/or FeNO ≥50 ppb, and/or blood eosinophils ≥0.3×109 cells/L. Continuous variables were presented as mean±standard deviation or median (Q1, Q3), and intergroup comparisons were conducted using t-tests, analysis of variance (ANOVA), or rank-sum tests. Categorical variables were analyzed using chi-squared or Fisher's exact tests. Repeated measures were analyzed using a mixed-effects model, and Cox regression was used to identify factors associated with complete cough resolution. Results: A total of 342 CVA patients (114 males and 228 females) were included, with a mean (±SD) age of (41.2±12.9) years (range 18-70 years). After 2 months of treatment, the median values for lung function parameters, FeNO levels, and sputum eosinophil counts of included CVA patients returned to near-normal levels, while the greatest improvement in cough severity was observed after 4 months of treatment. In 125 (36.5%) CVA patients, cough persisted despite 6 months of treatment. Compared with patients who achieved complete cough resolution, those with persistent cough were older, had a longer disease duration, higher baseline sputum neutrophil counts, lower sputum eosinophil counts, lower FeNO levels, and a lower proportion of type 2 inflammation [42.4% (53/125) vs. 65.3% (141/216)], P=0.001). Type 2 inflammation (HR=1.733, 95%CI: 1.188-2.528, P=0.004) was a predictive factor for complete cough resolution. Conclusions: CVA patients achieved the greatest improvement in cough after 4 months of anti-asthma treatment, suggesting that the treatment course may need to extend beyond 4 months. In some CVA patients, cough remained incompletely resolved despite treatment, which may be related to non-type 2 inflammation. 目的: 探究咳嗽变异性哮喘(CVA)抗哮喘治疗后咳嗽程度、肺功能和气道炎症变化及其预后的影响因素。 方法: 这是一项全国多中心、前瞻性观察队列研究。本研究于2017年12月至2020年1月从全国17家医院招募新诊断CVA患者,进行抗哮喘治疗及6个月随访,评估其咳嗽程度、肺功能、诱导痰细胞学和呼出气一氧化氮(FeNO)变化。符合以下至少一项定义为2型炎症:诱导痰嗜酸性粒细胞百分比≥3%,FeNO≥50 ppb,或外周血嗜酸性粒细胞计数≥0.3×10⁹/L。计量资料以x¯±s或M(Q1,Q3)表示,组间比较采用t检验、方差分析或秩和检验,计数资料采用卡方检验或Fisher精确检验,重复测量数据采用混合效应模型,并运用Cox回归分析咳嗽完全缓解的相关因素。 结果: 共纳入342例CVA患者,其中男114例,女228例,年龄18~70(41.2±12.9)岁。治疗2个月后,患者肺功能指标、FeNO及诱导痰嗜酸性粒细胞百分比的中位值均基本恢复至正常范围,在治疗4个月时,患者的咳嗽症状达到最大程度改善。125例(36.5%)CVA患者经6个月治疗咳嗽仍未能完全缓解。与咳嗽完全缓解CVA患者相比,咳嗽未能完全缓解CVA患者年龄更大、病程更长、基线期的诱导痰中性粒细胞百分比更高、诱导痰嗜酸性粒细胞百分比、FeNO水平及2型炎症比例[42.4%(53/125)比65.3%(141/216),P=0.001]更低。2型炎症(HR=1.733,95%CI:1.188~2.528,P=0.004)是咳嗽完全缓解的预测因素。 结论: CVA患者经过抗哮喘治疗4个月后咳嗽获得最大改善,提示抗哮喘治疗疗程可能需要持续4个月以上。部分CVA患者经治疗后咳嗽仍不能完全缓解,可能与非2型炎症有关。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lai KF, Zhan WZ, Jiang ZY, et al. [A multicenter, prospective, observational study of cough variant asthma in China: clinical features, airway inflammation, and prognosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 41218858. doi:10.3760/cma.j.cn112147-20250402-00180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。